CHA AI Healthkare Overview
CHA AI Healthcare is a small KOSPI-listed company in transition. Its revenue base is still the JAYJUN cosmetics business: sheet masks and skincare sold mainly into China, plus Korea, Japan and other export markets. In 2026, cosmetics accounted for essentially all reported revenue. After CHA Biotech Group took control in October 2025, the company was renamed, appointed group executives to its board, and redefined itself as the listed vehicle for the group's AI and medical-IT ambitions. Its main strategic asset is a minority stake of roughly 36.6% in Kakao Healthcare, acquired in December 2025 alongside affiliate CHA Cares. The stated plan is for the company to act as the executor of hospital IT infrastructure build-out and operation, with Kakao Healthcare supplying AI and data capability for a "Physical AI" in-hospital model. A KRW 52.6bn, five-year supply contract with Japan's Nissho Medical (June 2026) is the first large disclosed commercial anchor. Losses, convertible-bond overhang and dependence on related parties remain defining features.
What the company does today
CHA AI Healthcare currently has two business layers.
1. Legacy operating business: cosmetics (JAYJUN). The company develops, outsources manufacturing of, and sells skincare products under the JAYJUN brand and related brands. Its core category is the sheet mask, especially multi-step premium masks. It has extended into ampoules, creams, sun care, cleansing and sleeping packs. According to Butler.works, cosmetics made up 100% of revenue on a Q2-2026 basis. The company no longer owns a mask factory. In July 2019 it carved its Incheon plant out into a subsidiary, JKM, and sold 100% of JKM to Kolmar's mask subsidiary Kolmask for KRW 32bn (Dealsite, 4-Nov-2019). The business therefore runs an asset-light, brand-owner model with contract manufacturing.
2. New strategic layer: AI healthcare, medical IT and global healthcare. At the 27-Oct-2025 EGM, shareholders approved the name change and added AI medical solutions and global healthcare as business purposes (Asia Economy, 13-Oct-2025; Dealsite, 22-Oct-2025). When the Kakao Healthcare deal closed on 23-Dec-2025, the company said it would develop hospital IT infrastructure build-out and operation as its core growth engine. Under that plan, CHA AI Healthcare executes and operates hospital IT, Kakao Healthcare provides AI and data capabilities, and the company aims for an integrated build-operate-upgrade-data model rather than one-off projects (Asia Economy and Dealsite, 24-Dec-2025). No medical-IT revenue had been separately reported through H1-2026.
Company's own description
No English annual report exists, and the Korean business report (사업보고서) text could not be retrieved directly. The company's public statements describe two aims:
-
To move beyond being a simple beauty company and become a company that combines medical care and healthcare.
-
To become a "total life-care platform" spanning preventive medicine through life-stage-specific health management, using group channels such as CHAUM's power-aging wellness centre and anti-aging/aesthetics services (company statements reported by Asia Economy and The Guru, 13-Oct-2025).
For the cosmetics brand, the post-acquisition philosophy is "Reset Your Skin Algorithm," with "Skin Longevity" as the core brand vision. The brand is being repositioned as an ingredient-led bio-skincare brand (Fintech Times, 1-Sep-2026).
Revenue model
| Revenue stream | Model | Status (latest available) |
|---|---|---|
| Cosmetics product sales (export and domestic) | Product sales via distributors, cross-border e-commerce, online B2C and retail (e.g., Daiso, Don Quijote) | ~100% of revenue (Q2-2026, Butler.works) |
| Home shopping (TV) | Product sales | Discontinued in 2025; the company moved to online B2C to improve profitability (IB Tomato, 29-Jul-2025) |
| Hospital IT build-out and operation | Project plus recurring operation/service (stated intent) | Strategy stated Dec-2025. Revenue not separately disclosed through H1-2026. |
| Nissho Medical long-term supply contract | Supply (product/service scope not detailed in sources reviewed) | Signed Jun-2026. KRW 52.6bn through 22-Jun-2031. |
| Equity investment income | Equity-method share of Kakao Healthcare results | Equity-method losses recognized (IB Tomato, 25-Jun-2026) |
Value-chain position, customers and end markets
Value chain: Brand owner and marketer for cosmetics, with manufacturing outsourced. In healthcare, it is positioned as an intended integrator and operator of hospital IT infrastructure inside the CHA group ecosystem.
Customer types: Overseas distributors and platforms (China, including the JD.com partnership; Japan, via distributor PlanPlus; Southeast Asia, the Americas, Europe), domestic online consumers, and value retail (Daiso). In healthcare, the target customers are hospitals and medical institutions, including CHA group hospitals in 6 countries.
End markets: Mass and premium skincare, with China as the historical core. Medical IT and digital health in Korea and Japan.
Independent characterization
At present, CHA AI Healthcare is better described as a listed holding-and-transition vehicle with a shrinking cosmetics business than as an operating AI-healthcare company. Its consolidated revenue was KRW 7.3bn in FY2025, and cosmetics accounts for all of it. Most of its balance sheet sits in an equity-accounted stake in a loss-making digital-health company, Kakao Healthcare. Most of its strategic options depend on related parties in the CHA group: CHA Cares, CHA Healthcare, CHA Meditech and CHAUM. The 2026 Nissho Medical contract is large relative to the revenue base, at 720% of FY2025 revenue. Its revenue-recognition profile and product scope are not described in the sources reviewed. Investors should treat the AI-healthcare narrative as an option on group synergies, not as an established revenue line.
Strategy
Stated corporate strategy (themes, paraphrased from company statements)
-
From beauty to medical-healthcare convergence: Move beyond being a beauty company and become a combined medical and healthcare company (EGM announcement, Oct-2025).
-
Total life-care platform: Combine K-beauty brand strength with AI healthcare across group channels (CHAUM power-aging wellness centre, anti-aging/aesthetics), covering preventive care through life-stage health management.
-
Hospital IT as the core growth engine: Act as the executor of hospital IT build and operation, and earn recurring revenue through an integrated model of build, operation, upgrade and data use (Dec-2025).
-
"Physical AI" in hospitals: Embed AI directly into hospital operations, using Kakao Healthcare's AI and data capability.
-
JAYJUN rebrand: "Reset Your Skin Algorithm" and "Skin Longevity," with an ingredient-led bio-skincare repositioning and an expanded high-efficacy lineup using CHA group technology. The stated aim is to offer ingredient-focused skincare at reasonable prices (Sep-2026).
Initiatives in the last 24 months
| Date | Initiative | Detail | Source |
|---|---|---|---|
| H1-2025 | Channel restructuring | Exit from home shopping, move to online B2C, Daiso entry | IB Tomato; Asia Economy |
| Apr-2025 | Product | PDRN Porcelain Ampoule launch | Asia Economy |
| Jun-2025 | China channel | JD.com collaboration via a Chinese local government link | Asia Economy (12-Jun-2025) |
| 2,025 | Japan entry | Dr.Jayjun via PlanPlus and Don Quijote | The Guru |
| Jul-2025 | New business purposes (pre-CHA) | Medical, financial-product investment, and overseas equity acquisition purposes added. CB funding plan delayed twice. | IB Tomato (29-Jul-2025) |
| Oct-2025 | Rename and AI-healthcare purposes | EGM approvals | Asia Economy; Dealsite |
| Oct-2025 | Financing | KRW 40bn 36th CB | IB Tomato |
| Nov–Dec-2025 | Kakao Healthcare stake | Strategic collaboration agreement and equity stake | Dealsite; Asia Economy |
| Jun-2026 | Japan supply | Nissho Medical, KRW 52.6bn to 2031 | Money Today |
| Sep-2026 | Brand | Skin Longevity rebranding | Fintech Times |
ESG/sustainability commitments, cost programmes with targets, and medium-term financial targets: None publicly disclosed.
Associate-level target: Kakao Healthcare aimed to reach break-even in Q4-2026 (IB Tomato, 25-Nov-2025). IB Tomato (25-Jun-2026) reported that this timeline had slipped.
Products & Services
Cosmetics (JAYJUN and related brands)
| Product / line | Description and key claims | Target customer / market | Launch / latest version | Pricing model | Source |
|---|---|---|---|---|---|
| Black Water Light (Black 물광) Premium Mask, 3-STEP | Three-step format (cleanser, essence, sheet mask in one kit). Flagship product. Sold in 30+ countries; cumulative global shipments of 1.4bn+ sheets. | China core; global | Original c.2015. 1-step mask-only renewal Jul-2021 ("Black Water Light Hydro Mask"). | Retail product; price not disclosed | The Guru (Japan launch article); eToday (19-Jul-2021) |
| Intensive Shining Premium Mask, 3-STEP | Whitening and firming mask with eye-area care. 400M+ sheets sold cumulatively. 1-step version "Intensive Blooming Mask" (2021). | China; global | Original c.2015–16. Renewed 2021. | — | The Guru; eToday (2021) |
| Rose Blossom Mask | Long-selling mask cited as a China steady-seller | China | — | — | Asia Economy (29-Aug-2025) |
| JAYJUN Collagen Skin Fit Mask | Elasticity/firming mask | China | — | — | Fintech Times (1-Sep-2026) |
| Hyaluronic Acid Hydrating Mask and line | Hydration mask. 2025 line extensions include sunscreen and cleansing foam. | China; Korea online | Line extension 2025 | — | Fintech Times (2026); Asia Economy (12-Jun-2025) |
| PDRN Porcelain Ampoule | Contains 100%-purity PDRN plus multi-hyaluronic acid and ceramide. Positioned for skin-barrier and texture care. | Korea; export | Apr-2025 | — | Asia Economy (12-Jun-2025) |
| Okra Phyto Mucin Skincare | Plant-mucin skincare line | Korea; export | Apr-2021 | — | Asia Economy (9-Sep-2021) |
| Sleeping packs | Overnight mask packs. Sales surged in China c.2021. 3 SKUs in Daiso (2025). | China; Korea value retail | 2021 onward | Value-retail pricing at Daiso | eToday (2021); Asia Economy (Jun-2025) |
| Dr.Jayjun (닥터제이준) | Derma/functional brand. Japan-specific reformulation launched via Don Quijote, with PLAZA, LOFT and drugstores planned. 2020 MOU with an acne-specialist clinic. | Japan; Korea derma channel | Japan launch 2025 | — | The Guru; Asia Economy (30-Oct-2020) |
| MEZCLAR (메즈클라) | BB cream and essence BB. Together with the new hyaluronic-line items, reported cumulative sales of 800k units and KRW 18bn. | Korea; export | c.2024–25 | — | Asia Economy (12-Jun-2025) |
| Genie H (지니에이치) | Functional/clean-beauty line cited as a key line in 2025 | Korea | — | — | Hankyung (30-Sep-2025) |
| Full skincare range | Toners, essences, serums, creams, eye creams, sun care, cleansing, body and hair care | Global | Ongoing | — | Lazada Brand Wiki; Yahoo profile |
Historical/other: Jayjun H&B health-functional foods, such as products containing SEANOL® (an ingredient with US FDA NDI notification), including "iSeanol Plus" and "Seanol Q Premium" (eToday, 2-Dec-2019). Medical-aesthetic projects at RF Tech/RF Bio (HA filler, botulinum toxin; 2020).
Planned: A high-efficacy, active-ingredient skincare lineup drawing on CHA Biotech Group technology under the "Skin Longevity" vision (Fintech Times, Sep-2026). Analysts have flagged possible synergy with CHA Meditech's CELLTERMI exosome skin-booster line (Revive EX), which could use JAYJUN's China and Japan distribution. This is speculative, and the group said in Oct-2025 that no concrete plan was ready for disclosure (Dealsite, 28-Oct-2025).
Healthcare / medical IT (stated, pre-revenue)
| Offering | Description | Target customer | Status | Source |
|---|---|---|---|---|
| Hospital IT infrastructure build-out and operation | Company to act as the execution entity for hospital IT build and operation, followed by ongoing upgrades and data use (integrated operating model) | Hospitals, starting with the CHA group network | Strategy declared Dec-2025. No disclosed revenue. | Asia Economy and Dealsite (24-Dec-2025) |
| "Physical AI" in-hospital business model | AI deployed directly into hospital operations and infrastructure, with Kakao Healthcare supplying AI and data capability | Hospitals | Concept stage | Same |
| Nissho Medical supply programme | KRW 52.6bn long-term supply contract to Jun-2031. Product/service scope not specified in sources reviewed. | Nissho Medical (Japan) | Signed Jun-2026 | Money Today via StockHub |
Associate's products (Kakao Healthcare — not consolidated)
| Product | Description |
|---|---|
| PASTA | AI-based mobile health-management app |
| HRS, Haycorn | Medical data businesses |
| KareChat | Hospital concierge service |
Source: Dealsite and Kormedi (19-Nov-2025). Kakao Healthcare targeted break-even in Q4-2026 (IB Tomato, 25-Nov-2025).
Financial Narrative
All figures are K-IFRS consolidated, KRW 100M (억원), from Butler.works (DART-derived) unless noted. Blank cells mean the figure was not available in the sources reviewed. Margins, growth and ratios are derived.
Income statement
Revenue CAGR FY2021–FY2025: -22.7% per year (derived: (73/205)^(1/4) − 1).
- Share counts changed materially (Jun-2025 rights issue, later issuance and CB activity).
Dividends per share: 0 in all years (no dividend; Butler.works shows no dividend yield).
Gross profit and EBITDA: Not publicly available in the sources reviewed.
FY2025 revenue cross-check: The Nissho Medical contract (KRW 52.6bn) was disclosed as 720.05% of the prior year's consolidated revenue. That implies FY2025 revenue of KRW 7.305bn, which matches the KRW 7.3bn reported by Butler.works.
Interim results (FY2026)
Sources: IB Tomato (25-Jun-2026); ETFshopping (from the half-year report filed 12-Aug-2026). H1 figures are derived sums.
Balance sheet
FY2024 source: Digital Today AI disclosure (27-Oct-2025), "latest settlement" consolidated basis.
Other balance-sheet data points:
Cash and equivalents: KRW 5.3bn at 30-Sep-2025 (IB Tomato, 25-Nov-2025).
Convertible bonds: 36th unsecured private CB, KRW 40bn, issued Oct-2025. Convertible into 4,823,926 shares (implied conversion price ≈ KRW 8,292, derived; it may since have been reset under the conversion-price adjustment disclosed 20-Jul-2026).
Implied book equity, latest: About KRW 80bn, derived from market cap of KRW 85.4bn ÷ P/B of 1.05–1.07 (Butler.works, StockHub). This is a large step-up from KRW 29.6bn at FY2024. It is consistent with the Jun-2025 KRW 10bn rights issue, later equity issuance, and the FY2025 and H1-2026 net profits.
Investment in associates: The Kakao Healthcare stake (36.58%) was acquired for about KRW 10bn in purchase price per IB Tomato (21-Nov-2025), plus a separately announced KRW 10bn primary investment (Dealsite, 19-Nov-2025).
Consideration discrepancy: Dealsite and Medigate (19-Nov-2025) state that CHA Cares and CHA AI Healthcare together paid KRW 70bn to Kakao for Kakao Healthcare shares, with CHA AI Healthcare separately investing an additional KRW 10bn. IB Tomato (25-Nov-2025) puts CHA AI Healthcare's share purchase at about KRW 10bn for 36.85%. CHA Cares' consolidated audit report records total consideration for the Kakao Healthcare acquisition of KRW 80bn (IB Tomato, 25-Jun-2026). The split of consideration between CHA Cares and CHA AI Healthcare should be confirmed from DART.
Cash flow
Cash-flow statements were not available in the sources reviewed. The FY2025 financing inflows that are known are:
-
KRW 10bn rights issue to MetaX No.1 (Jun-2025)
-
KRW 40bn 36th CB (Oct-2025)
Ratios
FY2024 ratios derived from the FY2024 figures. Latest ROE TTM is 0.49% per StockHub (Sep-2026).
ROIC, current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: Not computable from the sources reviewed. EBITDA is negative in all reported years, so net debt/EBITDA and interest coverage are not meaningful.
Commentary on trends, inflections and drivers
Revenue: a structural decline in cosmetics. JAYJUN grew rapidly in China in 2015–2017. Revenue then fell after the THAAD-related Chinese restrictions on Korean consumer brands; the company itself attributed its losses to post-THAAD China weakness (Asia Economy, 12-Aug-2020). By 2020 quarterly revenue was about KRW 10.5bn, down 31% YoY in Q2-2020. Annual revenue then fell from KRW 20.5bn (FY2021) to KRW 6.2bn (FY2022), recovered to KRW 17.0bn (FY2023) and KRW 15.7bn (FY2024), and halved to KRW 7.3bn (FY2025). Management said the FY2025 decline was driven by the deliberate exit from home shopping in favour of online B2C, and said operating profit was being held roughly steady (IB Tomato, 29-Jul-2025). The reported operating loss nevertheless widened from KRW 5.4bn to KRW 7.5bn. That widening probably also reflects deal-related and transition costs in H2-2025, though this is not confirmed.
Profitability: chronic operating losses. The company has had an operating loss in every year from FY2021 to FY2025, totalling KRW 51.1bn on cumulative revenue of KRW 66.7bn (derived). The loss narrowed from FY2021 to FY2024 as costs were cut, then widened in FY2025.
Net income: driven by non-operating items. Net losses exceeded operating losses in FY2021–FY2022 (KRW -39.8bn and -21.7bn). Likely causes are valuation losses on affiliate derivatives and investments, a recurring theme since at least 2020 (Asia Economy, 14-Aug-2020). FY2025 turned to a small net profit of KRW 1.4bn despite an operating loss of KRW 7.5bn. Q2-2026 showed a net profit of KRW 10.4bn against an operating loss of KRW 1.1bn. These swings show that reported earnings currently reflect portfolio and valuation events (Kwanglim, Kakao Healthcare, CB derivatives) more than operations. The specific drivers were not disclosed in the sources reviewed.
Balance sheet: transformed by the 2025 recapitalization. The FY2024 balance sheet was small (assets KRW 38.9bn) with low leverage (liabilities/equity 31%). The KRW 40bn CB and the Kakao Healthcare investment changed both sides of the balance sheet. The CB, its possible derivative liabilities, and the equity-method investment are now the dominant items.
Inflection to watch: The Nissho Medical contract averages about KRW 10.5bn per year over five years if spread evenly (derived: KRW 52.6bn ÷ ~5 years). That is about 1.4x FY2025 revenue. It is the first disclosed revenue source that could change the company's scale. H1-2026 revenue of KRW 4.8bn shows it had not yet been recognized in meaningful volume by mid-year.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Relationship / stake | Source |
|---|---|---|---|
Ultimate group | CHA Hospital / CHA Biotech Group | Group parent ecosystem. CHA Biotech (KOSDAQ: 085660) is the listed flagship. | Multiple |
Intermediate | CHA Cares Co., Ltd. (차케어스) | CHA Biotech affiliate. Founded 2000. Hospital facility management, hospital contact centres, IT/mobile/digital platforms. FY2025 revenue KRW 67.8bn, operating loss KRW 0.04bn, net loss KRW 13.7bn. | Asia Economy (13-Oct-2025); IB Tomato (25-Jun-2026) |
Holding vehicle | MetaX No.1 Investment Partnership | CHA Cares holds 8,538 of 10,002 units (85.4%, Dealsite). Daily Pharm reports 89.0%. | Dealsite (2-Oct-2025); Daily Pharm (Nov-2025) |
Listed company | CHA AI Healthcare (025620) | Operating company | — |
Associate | Kakao Healthcare Corp. | 36.58% held by CHA AI Healthcare at end-2025. CHA Cares 47.03%, Kakao 16.39% at end-2025. Post-second-tranche target: CHA Cares and CHA AI Healthcare combined 43.08%, Kakao 29.99%, external investors 26.93%. | IB Tomato (25-Jun-2026); Dealsite (19-Nov-2025) |
Legacy holding | Kwanglim Co., Ltd. (광림) | Jayjun was Kwanglim's largest shareholder (Ssangbangwool-era circular structure). Kwanglim is in delisting proceedings and disposal is expected. | Dealsite (22-Oct-2025) |
Legacy subsidiaries | RF Tech / RF Bio; Jayjun H&B (incl. Mongolia entity); US entity | — | Asia Economy (2020); eToday (2019) |
Revenue by Segment (KRW) and Segment Margins & Growth (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue, consolidated (KRW 100M) | 170 | 157 | 73 |
Operating income, consolidated (KRW 100M) | -102 | -54 | -75 |
Operating margin (%) | -60.0 | -34.4 | -102.7 |
YoY revenue growth (%) | 174.2 | -7.6 | -53.5 |
Cosmetics share of revenue (%) | — | — | 100 |
Revenue by Segment (KRW)
| Metric (KRW 100M) | Q1-2026 | Q2-2026 |
|---|---|---|
Revenue (cosmetics) | 19 | 29 |
Operating income | -24 | -11 |
Net income | -46 | 104 |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 205 | 62 | 170 | 157 | 73 |
Revenue YoY growth (%) | — | -69.8 | 174.2 | -7.6 | -53.5 |
Operating income (KRW 100M) | -173 | -107 | -102 | -54 | -75 |
Net income (KRW 100M) | -398 | -217 | -68 | -95 | 14 |
Operating margin (%) | -84.4 | -172.6 | -60.0 | -34.4 | -102.7 |
Net margin (%) | -194.1 | -350.0 | -40.0 | -60.5 | 19.2 |
Income Statement (KRW)
| Metric (KRW 100M) | Q1-2026 | Q2-2026 | H1-2026 |
|---|---|---|---|
Revenue | 19 | 29 | 48 |
Operating income | -24 | -11 | -35 |
Net income | -46 | 104 | 58 |
Balance Sheet (KRW) and Margin Analysis (%)
| Metric | FY2024 |
|---|---|
Total assets (KRW 100M) | 389 |
Total liabilities (KRW 100M) | 93 |
Total equity (KRW 100M) | 296 |
Liabilities / equity (%) | 31.4 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%, on year-end equity) | -32.1 | — |
ROA (%, on year-end assets) | -24.4 | — |
ROE TTM latest (%) | — | 0.49 |
Revenue by Region (KRW)
| Region (KRW 100M) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 170 | 157 | 73 |
Share Price History
| Date | Price | Event | Source |
|---|---|---|---|
25-Jul-2025 | 7,300 | Close | IB Tomato |
30-Sep-2025 | 11,710 | Close (limit-up, CHA acquisition) | Hankyung |
1-Oct-2025 | 15,220 | Intraday, 9:30am (second limit-up) | Asia Economy |
27-Oct-2025 | 14,160 | Close (EGM day) | Digital Today |
22-Jun-2026 | 5,770 | Prior close (derived: 7,500 − 1,730) | Money Today via StockHub |
23-Jun-2026 | 7,500 | Intraday limit-up (Nissho contract) | Money Today via StockHub |
23-Sep-2026 | 4,745 | Close | StockHub |
28-Sep-2026 | 5,140 | Close (+8.9%) | MyDailyByte |
Valuation Multiples
| Multiple | CHA AI Healthcare | Source |
|---|---|---|
Market cap (KRW 100M) | 854 | Butler.works; StockHub |
P/E (TTM) | 8.27–10.48 | StockHub (8.27); Butler.works (10.48). Distorted by non-operating gains. |
P/B | 1.05–1.07 | Butler.works; StockHub |
EV/Sales (FY2025) | ≈11.7x on market cap/sales; EV not computable | Derived (85.4bn ÷ 7.3bn) |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
ROE (TTM) | 0.49% | StockHub |
Rank by market cap in sector | 78th of 121 (Household & Personal Products) | StockHub |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. 0 broker reports (StockHub). |
Dividend history / policy | No dividends paid in FY2021–FY2025. No stated policy. |
Buyback authorizations | None disclosed. Treasury shares 0.06%. |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt instruments | 36th unsecured private CB, KRW 40bn (Oct-2025). Convertible into 4,823,926 shares before adjustments. |
Equity issuance (last 18 months) | KRW 10bn rights issue, Jun-2025 (3,241,491 shares). |
Analyst Conclusions
Management guidance
No quantitative guidance has been issued. The qualitative direction is:
-
Hospital IT build and operation as the core growth engine
-
A Physical-AI hospital model with Kakao Healthcare
-
Rebuilding JAYJUN as a "Skin Longevity" bio-skincare brand
Consensus expectations
None. There is no sell-side coverage.
Bull case
-
Contracted step-change in revenue. The Nissho Medical contract (KRW 52.6bn to Jun-2031) is worth about KRW 10.5bn per year if spread evenly. That alone would roughly double to triple the FY2025 revenue base of KRW 7.3bn.
-
Captive demand from a large healthcare group. CHA group's 77 platforms in 6 countries, its growing smart-hospital IT business, and projects such as the Yongsan senior residence give the company a pipeline of related-party hospital-IT work that standalone peers lack.
-
Kakao Healthcare optionality. If Kakao Healthcare reaches break-even (its original target was Q4-2026), equity-method losses would stop and the 36.58% stake could be re-rated. The stake was acquired as part of a KRW 100bn funding round.
Bear case
-
Dilution. Potential overhang equals 79.9% of shares outstanding, including 4.82M CB conversion shares. Conversion-price resets (Jul-2026) increase the share count if the stock stays weak.
-
No operating proof. Revenue fell 53.5% in FY2025. Operating losses persisted through H1-2026 (KRW -3.5bn). There is no disclosed medical-IT revenue, and synergy had not materialized as of Jun-2026.
-
Group financial pressure and related-party risk. CHA Biotech's H1-2026 operating loss was KRW 58.9bn, and it is selling subsidiary stakes for liquidity. Minority shareholders of a small listed vehicle are exposed if group needs take priority.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q3-2026 report | ~14-Nov-2026 | First visible Nissho Medical revenue; operating loss trajectory |
| Kakao Healthcare results / break-even | Q4-2026 to 2027 | Equity-method loss size; second-tranche completion |
| First hospital-IT contract disclosure | Rolling | Contract size, counterparty (related party or third party), and recurring share |
| CB conversions / price resets | Rolling | Share count; MetaX No.1 stake dilution |
| Kwanglim stake disposal | Rolling | Proceeds versus carrying value |
| FY2026 business report | ~Mar-2027 | Segment disclosure (whether medical IT is separated); auditor opinion |
| China channel recovery | Rolling | Korea–China relations; JD.com sales |
| JAYJUN bio-skincare launches with group actives | 2026–2027 | Exosome/PDRN product launches; Japan rollout |
| Group restructuring (CHA Cares–CHA Healthcare merger or IPO speculation) | Uncertain | Effect on control and related-party flows |
Analyst verdict
CHA AI Healthcare is best read as an early-stage restructuring story placed inside a larger group, not as an established AI-healthcare operator. Its reported business is still a small and shrinking cosmetics brand. FY2025 revenue was KRW 7.3bn, with operating losses in every year since at least FY2021, and earnings that swing with valuation and portfolio items rather than operations. The 2025 change of control to CHA Biotech Group added three things it did not have before: a credible controlling shareholder with a multinational hospital network, a 36.6% stake in Kakao Healthcare, and, in June 2026, a KRW 52.6bn five-year supply contract with Nissho Medical that is large relative to the company's size.
The investment question is whether those three assets turn into recurring, profitable revenue faster than dilution and associate losses erode per-share value. At about KRW 85bn of market cap, roughly 1.05x book, and about 12x trailing sales, the market already prices in substantial success, while the share price is near 52-week lows after a roughly 64% fall from post-acquisition peaks. The 36th CB and other potential issuance, together equal to about 80% of shares, are the main constraint on per-share upside.
Disclosure is thin. Segment, geographic, cash-flow and R&D data are not available in public sources, and the scope of the Nissho contract is not described. Any position therefore depends on primary DART documents. Before taking a view, an analyst should confirm three things: the revenue-recognition schedule and margin of the Nissho contract, the carrying value and loss trajectory of the Kakao Healthcare stake, and the current conversion terms of all outstanding CBs.
Verdict: a speculative, event-driven situation with high execution, dilution and governance risk. Q3-2026 results (Nissho revenue start) and the first disclosed hospital-IT contract are the key tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Appointed | Background | Compensation |
|---|---|---|---|---|
Yoon Kyung-wook (윤경욱) | CEO and inside director | 27-Oct-2025 | BA Business Administration, Korea University. Former Head of Strategic Planning, CHA Biotech. CEO of CHA Healthcare (led the 2024 consolidation of Singapore Medical Group). | Not publicly disclosed (Korean rules require individual disclosure only above KRW 500M) |
Song Jong-guk (송종국) | Inside director | 27-Oct-2025 | CEO, CHA Cares | — |
Kim Seok-jin (김석진) | Inside director | 27-Oct-2025 | CHA Hospital/Bio Group background | — |
Jang Hyung-soo (장형수) | Outside (independent) director | 27-Oct-2025 | — | — |
Kim Hyun-woo (김현우) | Statutory auditor | 27-Oct-2025 | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Period | CEO | Context |
|---|---|---|
c.2017–Mar-2019 | Lee Jin-hyung (founder), co-CEO with Pan Na from c.2018 | F&Republic control era |
Mar-2019–Aug-2020 | — | Lee resigned and remained a director |
Aug-2020– | Lee Jin-hyung (returned) | Cosmetics turnaround mandate |
By Jun-2025 | Son Sang-hoon (손상훈) | Cited as CEO in Jun-2025 (Asia Economy) |
By Aug-2025 – 27-Oct-2025 | Jeon Kyung-jae (전경재) | CEO at the Aug-2025 award ceremony. Resigned 27-Oct-2025. |
27-Oct-2025 – present | Yoon Kyung-wook | CHA group appointee |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Treasury shares | 0.06% | Butler.works |
Competitive Landscape
Key Competitors
| Competitor | Listing | Positioning vs. CHA AI Healthcare |
|---|---|---|
Amorepacific | KOSPI | Diversified K-beauty leader. Far larger scale and owned manufacturing. |
LG H&H | KOSPI | Diversified major with a strong China premium portfolio |
Mediheal (L&P Cosmetic) | — | Leading Korean sheet-mask brand; direct mask competitor |
Abib, Papa Recipe, Leaders Cosmetics (sheet-mask specialists) | Mixed | Direct mask competitors in China and global channels |
Able C&C (Missha) | KOSPI | Mass skincare, Japan presence |
Clio | KOSDAQ | Colour/skincare; strong Japan and US online |
Tonymoly | KOSPI | Value skincare including masks |
Korea Kolmar, Cosmax (ODM) | KOSPI | Not brand competitors. Supply-side players that enable low-barrier brand entry and so intensify competition. |
Ezcaretech | KOSDAQ | Hospital EMR/HIS and cloud HIS; direct hospital-IT competitor |
BIT Computer | KOSDAQ | Hospital information systems |
UBcare | KOSDAQ | Clinic EMR and healthcare data |
Lunit, Vuno, JLK, Coreline Soft | KOSDAQ | Medical-imaging AI. Adjacent, and expanding into Japan. |
Naver Healthcare and large IT services groups (LG CNS, Samsung SDS) | Various | Large-scale hospital digital transformation and AI |
Competitor Detail
| Metric | CHA AI Healthcare |
|---|---|
Revenue FY2025 (KRW 100M) | 73 |
Revenue growth FY2025 (%) | -53.5 |
Operating margin FY2025 (%) | -102.7 |



